Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- UIFCA Revolutionizes Financial Education with Elite Team of Investment Experts
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules. The posters, presented May 8-9, 2023, highlighted potential cost savings in both Medicare and commercially insured patient populations with use of the tests.
The analyses estimated cost savings in a hypothetical population of 1 million patients in a US Medicare or commercial payer setting over a 2-year time horizon. The results predicted that plans would save $600,000 to $3.9 million with use of the tests in the treatment pathways for managing pulmonary nodules.
The two posters assessing budget impact of the Nodify XL2 test, titled "Budget Impact of a Blood-Based Integrated Classifier Test to Reclassify Risk of Pulmonary Nodules in a US Commercial Payer Setting" and "Budget Impact of a Blood-Based Integrated Classifier Test to Down Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting," highlighted the cost-savings to payers by incorporating Nodify XL2 use, with cost-savings largely attributed to the ability of the test to reduce invasive procedures on benign nodules. Prior studies have shown that work up of benign nodules make up the majority of costs of pulmonary nodule management.
More on Colorado Desk
The two posters assessing budget impact of the Nodify CDT test, titled "Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Commercial Payer Setting" and "Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting," focused on the ability of the test to support earlier diagnosis of lung cancer leading to an increase in stage I diagnoses and improved patient outcomes. At earlier stages, patients are eligible for potentially curative surgical resection with a lower cost profile compared to standard of care therapies for advanced stage lung cancer.
"These data presented at ISPOR solidifies the transformative potential of our Nodify CDT and Nodify XL2 tests," said Scott Hutton, CEO of Biodesix. "Establishing the healthcare cost savings that result from broad use of the tests is an important step to showcasing the utility of the tests throughout the healthcare ecosystem. Our commitment is to pursue innovations that transform patient care while bringing economic balance to the healthcare system."
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
More on Colorado Desk
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Contacts
Media:
Robbie Lunt
robbie.lunt@biodesix.com
1-866-432-5930
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
The analyses estimated cost savings in a hypothetical population of 1 million patients in a US Medicare or commercial payer setting over a 2-year time horizon. The results predicted that plans would save $600,000 to $3.9 million with use of the tests in the treatment pathways for managing pulmonary nodules.
The two posters assessing budget impact of the Nodify XL2 test, titled "Budget Impact of a Blood-Based Integrated Classifier Test to Reclassify Risk of Pulmonary Nodules in a US Commercial Payer Setting" and "Budget Impact of a Blood-Based Integrated Classifier Test to Down Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting," highlighted the cost-savings to payers by incorporating Nodify XL2 use, with cost-savings largely attributed to the ability of the test to reduce invasive procedures on benign nodules. Prior studies have shown that work up of benign nodules make up the majority of costs of pulmonary nodule management.
More on Colorado Desk
- Colorado Springs: Jessie Kimber inducted as Fort Carson Good Neighbor
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Colorado: Governor Polis: Real Results Delivered for Coloradans in 2025 Legislative Session
The two posters assessing budget impact of the Nodify CDT test, titled "Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Commercial Payer Setting" and "Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting," focused on the ability of the test to support earlier diagnosis of lung cancer leading to an increase in stage I diagnoses and improved patient outcomes. At earlier stages, patients are eligible for potentially curative surgical resection with a lower cost profile compared to standard of care therapies for advanced stage lung cancer.
"These data presented at ISPOR solidifies the transformative potential of our Nodify CDT and Nodify XL2 tests," said Scott Hutton, CEO of Biodesix. "Establishing the healthcare cost savings that result from broad use of the tests is an important step to showcasing the utility of the tests throughout the healthcare ecosystem. Our commitment is to pursue innovations that transform patient care while bringing economic balance to the healthcare system."
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
More on Colorado Desk
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Need a Rental Venue? Evergood Wines Hosts Parties, Reunions, and Nonprofits on Its Outdoor Patio
- Poor Richard's Celebrates 50 Years of Community, Culture, and Connection
- Colorado: Governor Polis Appoints Michal A. Lord-Blegen to the 17th Judicial District Court
- Colorado Springs: Mayor Yemi, City Councilmembers to host 2025 Report Out Community Tour
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Contacts
Media:
Robbie Lunt
robbie.lunt@biodesix.com
1-866-432-5930
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Filed Under: Business
0 Comments
Latest on Colorado Desk
- Shareholder Alert: Robbins LLP Informs Investors of the Civitas Resources, Inc. Class Action Lawsuit
- Free Peer Recovery Coaching Now Available for Rocky Mountain Health Plan Members Across Colorado
- ABM for Good™ Launches First Project with Build Change
- Colorado Tourism Office Celebrates 2025 National Travel & Tourism Week
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- State Launches Colorado Property Tax Map as a Central Source to Understand Taxing Jurisdictions and Property Tax Rates
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Carbonado Capital Investments Surpasses $700 Million AUM Under the Leadership of Gregory A. Thomas
- Ryleigh Norgrove Launches Dispatches from the Edge — Writing on Climbing, Land and Culture
- Mayor Johnston, Governor Polis, Attorney General Weiser, Senator Bennet, Congressman Neguse & Congresswoman Pettersen Release Letter to Colorado General Assembly on A.I.
- Governor Polis Sign Bills into Law Expanding Support Services and Increasing Safety in Colorado Schools
- ATTENTION NYSE: CIVI INVESTORS: Contact Berger Montague About a Civitas Resources Class Action Lawsuit
- Colorado: Governor Polis, Union Pacific Railroad Officials Celebrate Signing of Historic Partnership on Moffat Tunnel Lease Agreement and Mountain Passenger Rail Agreement
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador